Given that CD44 upregulation in patient samples and cell lines is also strongly correlated with an acquired resistance against the first line ovarian cancer therapeutics (53–57), we hypothesize that functional interaction between CD44 and STAT3 may be one of the driving mechanisms of ovarian cancer progression and therapy resistance, which deserves further attention. This evidence concerns the gene STAT3 and ovarian cancer.